Does Koyfin Have Backtesting? What It Tests and What It Cannot

No. Koyfin has no backtesting engine on any plan, including Premium at $79 a month and Advisor Pro at $299. We checked every public Koyfin page that would carry the feature if it existed, including Koyfin's own full plan comparison matrix and the pricing guide it publishes specifically for AI assistants, and the word "backtest" does not appear on any of them. This is not a case of a feature being hidden behind a login. Koyfin is a research and analytics terminal, and testing a rule across history is simply not something it does.

The reason people keep asking is that Koyfin Premium includes something called hypothetical performance, which sounds exactly like backtesting and is not. That distinction is worth understanding before you spend $948 a year expecting a capability you will not get.

What we checked, and what each check returned

All of this was run against Koyfin's public site on August 20, 2026 with an ordinary desktop browser user agent. Each check is a plain text search for "backtest" in the page source. Anyone can repeat the whole thing in about three minutes.

The third row is the one that settles it. Koyfin maintains a page at koyfin.com/pricing-llm-info that exists to be read by language models, and it walks through which plan fits which job across a dozen different workflows: stock research, dividend investing, ETF investing, portfolio tracking, advanced portfolio analysis, custom formulas, model portfolios, multi-custodian advisory work. Backtesting is not one of them. When a vendor writes a document whose entire purpose is to answer "which plan do I need for X" and X never includes backtesting, that is about as clear as a negative answer gets.

Is Koyfin's hypothetical performance the same as a backtest?

No, and this is the single most common source of confusion about Koyfin. Hypothetical performance, which sits on Premium as part of My Portfolio advanced analytics, models what a change to a portfolio you already hold would have done. You take your current holdings, adjust the weights or add a position, and Koyfin shows you how that modified allocation would have performed historically. It is a what-if on an allocation.

A backtest is a different operation. It takes a rule, something like "buy when the 50 day moving average crosses above the 200 day and sell when it crosses back," and executes that rule day by day across many years of history, generating entries and exits it was never told about in advance. The output is a trade list, a drawdown curve, a win rate and a benchmark comparison. One tests an allocation you chose. The other tests a decision process, and finds out how many times that process would have been wrong.

Can you backtest a screener on Koyfin?

You cannot. Koyfin's screener returns the list of companies matching your criteria as of right now, and there is no facility to run those same criteria back through history and see what a portfolio of the matches would have returned. This is a genuine gap and it is a common one across the category. Most screeners tell you what passes the filter today and stay silent on whether passing that filter has ever been worth anything.

It is a gap worth taking seriously rather than shrugging at, because the academic evidence on published screening criteria is not encouraging. McLean and Pontiff, writing in the Journal of Finance in 2016, tracked 97 return predictors that had been documented in peer-reviewed papers and found returns roughly 26% lower out of sample and 58% lower after publication. Screening rules built out of widely known metrics are drawn from exactly that population. If you build a screen on value or quality or momentum factors and never test it, you are assuming an edge that the literature says decays sharply once everybody can see it.

Which Koyfin plan would backtesting be on?

None of them, but it is worth walking the ladder because the answer changes what you should buy. Koyfin's five tiers, read off koyfin.com on August 20, 2026, are Free at $0, Plus at $39 a month billed annually, Premium at $79, Advisor Core at $209 and Advisor Pro at $299. Month to month those paid tiers are $49, $110, $239 and $349, a difference the Koyfin pricing breakdown covers in full because Koyfin does not display those monthly figures by default.

If backtesting were coming, Premium is where it would land, because Premium is where the analytical machinery lives: custom formulas, custom data series, risk statistics, short position support. It is not there. Upgrading from Plus at $39 to Premium at $79 buys you portfolio analytics and the ability to build your own metrics. It does not buy you a way to test a rule, and paying the extra $480 a year expecting one is the mistake this article exists to prevent.

The advisor tiers change the picture even less. Advisor Core and Advisor Pro are about client infrastructure rather than research depth: model portfolios, client portfolios, custodian integrations, branded proposals and reports. An advisor whose Koyfin output then has to become a client meeting presentation is doing a third job again, and turning a research report into a finished client presentation is its own piece of software rather than something a data terminal handles. None of that layer includes strategy testing either.

What can you use to backtest alongside Koyfin?

Plenty of people keep Koyfin for research and add something separate for testing, which is a reasonable stack. Prices below were verified at each vendor and the dates are noted, because pricing in this category moves and stale figures are the norm in most comparison articles.

Do you need Koyfin, a backtester, or both?

They answer different questions, and which you need depends on where you actually get stuck. Koyfin answers "what is this company and how does it compare," with ten years of financials and estimates on Plus, filings, transcripts, ETF holdings and a global universe. That is genuine value and it is priced well against anything institutional. A backtester answers "has this rule ever worked," and no amount of fundamental data substitutes for that.

The honest split is this. If you pick stocks one at a time on the merits of each business, Koyfin Plus at $39 is probably the whole tool you need and a backtester will mostly tell you things you were not going to act on anyway. If you have a repeatable rule, anything you could write down as a sentence that starts with "buy when," then not testing it is the expensive choice, and Koyfin cannot help you at any tier. Most people who ask this question turn out to be in the second group without realizing it, because a screen is a rule whether or not you thought of it that way.

Bailey, Borwein, Lopez de Prado and Zhu made the related point in the Notices of the American Mathematical Society in May 2014: with only five years of daily data, testing more than about 45 independent configurations of a strategy will near enough guarantee you an in sample Sharpe ratio of 1.0 whose expected out of sample performance is zero. That cuts both ways here. It is an argument for testing on a long history rather than a short one, and it is an argument against treating any single good looking result as an answer. Neither problem gets solved by having more fundamental data.

The short version

Koyfin does not backtest, on any plan, and it does not claim to. Its own AI-facing pricing guide covers a dozen use cases and backtesting is not among them. Premium's hypothetical performance models a change to an allocation you hold, which is a useful feature and a different one. If you want Koyfin for research, buy it for research: Plus at $39 a month billed annually covers most individual investors, Premium at $79 is for people who build their own calculations, and the Koyfin alternative comparison covers what else is in that space. When you want to know whether a rule held up across two decades, that is a separate purchase, and it is the one thing we do.

Educational analysis only. Past performance does not guarantee future results. Prices were read at each vendor on the dates noted and change without notice.